New psoriasis drug shows promise in early trial
NCT ID NCT05725057
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo for 28 days, then were monitored for 30 more days to check safety. The main goal was to see if the drug is safe and tolerable, with some measures of how well it works against psoriasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accellacare North London
Northwood, United Kingdom
-
Accellacare Northamptonshire
Corby, United Kingdom
-
Accellacare South London
Orpington, United Kingdom
-
Accellacare Warwickshire
Coventry, United Kingdom
-
Accellacare Yorkshire
Shipley, United Kingdom
-
MEU
Manchester, United Kingdom
Conditions
Explore the condition pages connected to this study.